Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cocrystal Pharma Inc
(NQ:
COCP
)
1.750
UNCHANGED
Streaming Delayed Price
Updated: 9:30 AM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cocrystal Pharma Inc
CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event
August 15, 2024
Via
ACCESSWIRE
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap
March 05, 2024
Via
ACCESSWIRE
Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast
January 23, 2023
Phoenix, Arizona--(Newsfile Corp. - January 23, 2023) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("Cocrystal," "Cocrystal...
Via
Newsfile
Exposures
COVID-19
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022
December 01, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A
November 17, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
November 14, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Participate in Two Investor Conferences in November
November 02, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza
November 01, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
October 26, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Present at the LD Micro Main Event XV
October 19, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022
October 13, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19
October 11, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
October 05, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
October 03, 2022
From
Cocrystal Pharma, Inc.
Via
GlobeNewswire
Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast
August 03, 2022
Phoenix, Arizona--(Newsfile Corp. - August 3, 2022) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("the Company"),...
Via
Newsfile
Exposures
COVID-19
New COVID-19 Vaccination Mandates Make Rapid COVID Tests More Essential Than Ever
August 19, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
California and NYC Order Mandatory COVID-19 Testing Among Municipal Workers
August 03, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.